A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer

PHASE3RecruitingINTERVENTIONAL

Enrollment

680

Participants

Timeline

Start Date

May 17, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG

BL-B01D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Docetaxel

Administration by intravenous infusion for a cycle of 3 weeks.

Trial Locations (1)

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY